

IMPACT SUCCESS STORIES



“ Personalisation of immunosuppression by monitoring viral load post kidney transplantation - a randomised controlled phase II trial (TTV GUIDE TX)

Through cutting-edge research supported by Horizon Europe, we aim to create a transformative 'immuno-meter' that ensures optimal immune response, minimizing risks of infection and rejection while maximizing patient well-being.



Gregor Bond, MD, PhD
Associate Professor,
Medical University of Vienna



1. Describe your project through three key words / key phrases that identify it.

The project emphasizes "Individualized Immunosuppression" with a focus on "TT Virus Monitoring" for optimized "Kidney Transplant Care," aiming for targeted and effective patient treatment strategies.

2. In terms of impact, what are the most concrete results your project has or will achieve?

The most concrete result would be the establishment of a novel method for individualizing immunosuppressive therapy for kidney transplant recipients based on TT virus monitoring. This approach aims to reduce the risk of infection, rejection, and side effects while optimizing patient outcomes.

However, the TT virus isn't just about kidneys. It's getting attention in other medical areas too. Take cancer, for instance. Traditional drugs can be harsh, damaging healthy cells along with tumors. But there's a shift towards using immune modulators, which activate your own immune system and could be a game-changer.

In the realm of rheumatology, where the immune system plays a big role too, the SQUEEZE project, which is also coordinated here at Medical University of Vienna is testing how TTV might relate to how people respond to the drugs they receive against rheumatoid arthritis.

3. Please describe your project overall impact at the European level

Our project significantly contributes to European healthcare by advancing kidney transplant care through individualized immunosuppression strategies based on TT virus monitoring. This approach not only aims to improve patient outcomes but also sets a precedent for personalized medicine in transplant immunology across Europe. By enhancing the effectiveness of treatments and reducing complications, the project is poised to have a substantial impact on public health and healthcare practices throughout the EU.

4. As an applicant, what advice would you have wanted in the Horizon project design process? What support did you receive from National Contact point (NCP) and your organisation, and what improvement of support would you benefit from?

Enhanced support for scientific project coordination is needed, particularly in managing administrative tasks like reporting and contract amendments. We benefited from collaboration with EUTEMA, although revisiting the EC's administrative responsibility policy could be beneficial. The National Contact Point at the Austrian Research Promotion Agency provided valuable proposal guidance and training. Further investment in training for young scientists to navigate EU grants would also be advantageous.

Visit the full catalogue of all [impact success stories](https://www.healthncp.net/) at our website: <https://www.healthncp.net/>



HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 101057279